Anzeige
Mehr »
Sonntag, 17.08.2025 - Börsentäglich über 12.000 News
Neue Bohrergebnisse, Sichtgold und eine 7-fache Bewertungslücke, die zu groß ist, um sie zu ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
15.08.25 | 21:59
0,628 US-Dollar
+15,81 % +0,086
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
FrPlus Therapeutics Reports $3M in Stock Equity2
FrPlus Therapeutics meets Nasdaq equity requirement to maintain listing8
FrPlus Therapeutics GAAP EPS of -$0.01 beats by $0.07, revenue of $1.39M misses by $0.44M5
FrPlus Therapeutics Inc.: Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements70HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
► Artikel lesen
DoPlus Therapeutics Inc.: Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights131Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus...
► Artikel lesen
DoPLUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
DoCNSide-Assay von Plus Therapeutics mit vielversprechenden Ergebnissen bei leptomeningealen Metastasen1
DiPlus Therapeutics files to sell 33M shares of common stock for holders4
DiPLUS THERAPEUTICS, INC. - 8-K, Current Report2
DiPLUS THERAPEUTICS, INC. - S-1, General form for registration of securities2
31.07.Plus Therapeutics: Diagnostikplattform CNSide startet im August 2025 in Texas16
31.07.Plus Therapeutics Inc.: Plus Therapeutics Provides US Launch Update for its CNSide Diagnostic148CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden...
► Artikel lesen
23.07.Plus Therapeutics receives $1.6 million advance from CPRIT grant5
23.07.Plus Therapeutics announces $1.6 million advance payment from CPRIT3
23.07.Plus Therapeutics Inc.: Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT287HOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
► Artikel lesen
18.07.PLUS THERAPEUTICS, INC. - 8-K, Current Report5
15.07.Plus Therapeutics Inc.: Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ in Patients with Leptomeningeal Metastases5
08.07.Plus Therapeutics begins treatment in REYOBIQ dose optimization trial9
08.07.Plus Therapeutics Inc.: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases528HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
► Artikel lesen
30.06.Plus Therapeutics Inc.: Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases326Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award...
► Artikel lesen
Weiter >>
99 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1